A new Third Rock startup seeks a 'second golden age' of GPCR drug discovery based on Nobel laureate's work
Among the most prolific target classes in all of drug discovery, a group of membrane proteins known as G protein-coupled receptors (GPCR) have been the focus of hundreds of approved medicines over several decades. But a team out of Third Rock Ventures thinks there’s a lot more to learn about GPCRs, and it’s working with the godfather of the field to find a breakthrough.
With backing from Third Rock and a clutch of A-list biotech VCs on board, Septerna Therapeutics launched Thursday with $100 million in funding and an already bustling pipeline and new technology offering researchers their best-ever look at the function and shape of GPCRs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
